These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8370326)

  • 1. Comparative efficacy of ceftriaxone in experimental infections involving Bacteroides fragilis and Escherichia coli.
    Dezfulian M; Bitar RA; Bartlett JG
    Chemotherapy; 1993; 39(5):355-60. PubMed ID: 8370326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
    Brook I
    Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
    Brook I
    Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
    Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
    J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
    Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
    Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
    Brook I; Ledney GD
    J Antimicrob Chemother; 1994 Feb; 33(2):243-52. PubMed ID: 8182005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
    Beale AS; Gisby J
    J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacies of ticarcillin, ticarcillin/clavulanic acid, piperacillin and cefoxitin against polymicrobial infections in mice caused by Escherichia coli and Bacteroides fragilis.
    Beale AS; Gisby J
    Infection; 1991; 19(2):101-5. PubMed ID: 2050417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
    Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
    Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of Escherichia coli--Bacteroides fragilis pathogenic synergy in an intraabdominal infection model.
    Rotstein OD; Kao J
    Can J Microbiol; 1988 Mar; 34(3):352-7. PubMed ID: 3046726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-Lactamase produced by a highly beta-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections.
    Ajiki Y; Koga T; Ohya S; Takenouchi T; Yasuda H; Watanabe K; Ueno K
    J Antimicrob Chemother; 1991 Oct; 28(4):537-46. PubMed ID: 1761449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Bacteroides fragilis on mortality induced by Escherichia coli in an experimental infection treated with cefotaxime, aztreonam or gentamicin.
    Soriano F; Ponte C; Santamaría M; Castilla C
    J Antimicrob Chemother; 1989 Mar; 23(3):383-8. PubMed ID: 2659565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental intraabdominal abscess formation by Escherichia coli and bacteroides fragilis.
    Hagen JC; Wood WS; Hashimoto T
    Eur J Clin Microbiol; 1983 Feb; 2(1):43-9. PubMed ID: 6341050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
    Bartlett JG; Dezfulian M; Joiner K
    Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Candida albicans in the pathogenesis of experimental fungal/bacterial peritonitis and abscess formation.
    Sawyer RG; Adams RB; Rosenlof LK; May AK; Pruett TL
    Am Surg; 1995 Aug; 61(8):726-31. PubMed ID: 7618816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous injection of mice with bacteroides fragilis and Escherichia coli: role of Thioglycollate medium in the infectious process.
    Rodloff AC; Rodloff S; Fischer B; Hahn H
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 May; 254(3):405-12. PubMed ID: 6372324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.